RECRUITINGPhase 2INTERVENTIONAL
Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial
About This Trial
The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).
Who May Be Eligible (Plain English)
Who May Qualify:
- Meets DSM-5 AUD criteria of at least moderate severity
- Meets heavy drinking requirements (heavy drinking days, number of drinks) in past 30 days
- Desire to decrease alcohol consumption
- Limited lifetime hallucinogen use
Who Should NOT Join This Trial:
- Severe or moderate substance use disorder other than alcohol or nicotine in past 6 months
- Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis
- Active suicidal ideation or serious attempt within past 3 years
- Currently pregnant, nursing, or trying to become pregnant
- Any notable abnormality on ECG, physical exam, or routine medical blood laboratory test
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Meets DSM-5 AUD criteria of at least moderate severity
* Meets heavy drinking requirements (heavy drinking days, number of drinks) in past 30 days
* Desire to decrease alcohol consumption
* Limited lifetime hallucinogen use
Exclusion Criteria:
* Severe or moderate substance use disorder other than alcohol or nicotine in past 6 months
* Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis
* Active suicidal ideation or serious attempt within past 3 years
* Currently pregnant, nursing, or trying to become pregnant
* Any notable abnormality on ECG, physical exam, or routine medical blood laboratory test
Treatments Being Tested
DRUG
Psilocybin
Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
Locations (1)
University of Calgary
Calgary, Alberta, Canada